Factor | N (%) |
---|---|
Age (years) | |
median (range) | 67 (48–84) |
Sex | |
Male | 30 (69.8) |
Female | 13 (30.2) |
ECOG PSa | |
0 | 11 (25.6) |
1–2 | 32 (74.4) |
Disease status | |
Metastatic | 34 (79.1) |
Recurrence | 9 (20.9) |
Treatment line | |
Third line | 34 (79.1) |
Fourth line | 5 (11.6) |
Fifth line | 4 (9.3) |
CEAb (ng/mL) | |
median (range) | 11.6 (2.5–669.7) |
CA 19–9c (U/mL) | |
median (range) | 2762.7 (0–115,360.2) |
CRPd (mg/dL) | |
median (range) | 1.46 (0.03–10.0) |
Haemoglobin (g/dL) | |
median (range) | 11.4 (13.9–8.1) |
Albumin (g/dL) | |
median (range) | 3.5 (2.2–4.2) |
Germline BRCA mutation | |
Positive | 1 (2.3) |
Negative | 30 (76.7) |
Not assessed | 9 (20.9) |
Reason for discontinuation of 5-FU/LV + nal-IRIe | |
Progression | 42 (97.7) |
Intolerable toxicity | 1 (2.3) |